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Abstract
Background: Image-guided radiotherapy (IGRT) increases the accuracy of treatment delivery through daily target
localisation. We report on toxicity symptoms experienced during radiotherapy treatment, with and without IGRT in
prostate cancer patients treated radically.
Methods: Between 2006 and 2009, acute toxicity data for ten symptoms were collected prospectively onto
standardized assessment forms. Toxicity was scored during radiotherapy, according to the Common Terminology
Criteria Adverse Events V3.0, for 275 prostate cancer patients before and after the implementation of a fiducial
marker IGRT program and dose escalation from 74Gy in 37 fractions, to 78Gy in 39 fractions. Margins and planning
constraints were maintained the same during the study period. The symptoms scored were urinary frequency,
cystitis, bladder spasm, urinary incontinence, urinary retention, diarrhoea, haemorrhoids, proctitis, anal skin
discomfort and fatigue. Analysis was conducted for the maximum grade of toxicity and the median number of
days from the onset of that toxicity to the end of treatment.
Results: In the IGRT group, 14228 toxicity scores were analysed from 249 patients. In the non-IGRT group, 1893
toxicity scores were analysed from 26 patients. Urinary frequency ≥G3 affected 23% and 7% in the non-IGRT and
IGRT group respectively (p = 0.0188). Diarrhoea ≥G2 affected 15% and 3% of patients in the non-IGRT and IGRT
groups (p = 0.0174). Fatigue ≥G2 affected 23% and 8% of patients in the non-IGRT and IGRT groups (p = 0.0271).
The median number of days with a toxicity was higher for ≥G2 (p = 0.0179) and ≥G3 frequency (p = 0.0027), ≥G2
diarrhoea (p = 0.0033) and ≥G2 fatigue (p = 0.0088) in the non-IGRT group compared to the IGRT group. Other
toxicities were not of significant statistical difference.
Conclusions: In this study, prostate cancer patients treated radically with IGRT had less severe urinary frequency,
diarrhoea and fatigue during treatment compared to patients treated with non-IGRT. Onset of these symptoms
was earlier in the non-IGRT group. IGRT results in less acute toxicity during radiotherapy in prostate cancer.
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Background
Online image-guided radiotherapy (IGRT) in prostate
cancer refers to daily pre-treatment imaging and
immediate correction for the day to day movement of
the target [1,2], caused predominantly by bladder or rec-
tal filling [3]. Schallenkamp et al. reported that between
the planning CT and delivery of each fraction of radio-
therapy, prostate 3-D displacement ranged from 0.4 to
17 mm with a mean of 5.6 mm [4]. A geographical miss
of the prostate will result in increased dose delivered to
the adjacent structures.
In a large cohort of patients treated with IGRT for
prostate cancer, Lips et al. reported acute grade 2 (G2)
genitourinary (GU) toxicity in 47% and G2 gastrointest-
inal (GI) toxicity in 30% [5]. For comparison, Lips et al.
tabulated the acute toxicities from different non-IGRT
studies. Acute G2 GU toxicity was seen in 24-49% of
patients treated with non-IGRT and acute G2 GI toxi-
city was seen in 28-57% [5]. In another cohort of 238
patients treated with IGRT, Soete et al. reported a
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toxicity [6]. Conversely, Ghadjar et al. found 56% had
G2 GU toxicity but only 3% had G2 GI toxicity [7].
Other studies have reported varying IGRT acute toxicity
rates with tomotherapy [8] and conformal radiotherapy
[ 9 ] .T h ew i d er a n g eo fG Ua n dG Is i d ee f f e c t sa c r o s s
studies is due to differences in methodology employed
across studies, thus making comparison difficult to
interpret. These studies use different radiotherapy plan-
ning dose constraints, treatment delivery techniques,
target margins, toxicity assessment tools and patient
populations across different treatment centres with vary-
ing protocols. The exact benefit of IGRT in terms of
acute toxicity reduction compared to non-IGRT treated
patients has yet to be determined.
In this study, we report the toxicity profile for a large
cohort of prostate cancer patients treated with and with-
out IGRT. In 2007, our department implemented an
IGRT program for all prostate cancer patients as stan-
dard [10]. As quality assurance, we started collecting
acute toxicity data prospectively at the end of 2006,
before the implementation of IGRT, so that we would
have toxicity data on patients before commencing the
IGRT program and after. All patients in both groups
were treated with the same protocols, target volume
expansion margins, planning constraints and underwent
the same toxicity assessments.
Patients and Methods
Between the 22
nd of June 2006 and the 24
th of June
2009, 291 patients who received radiotherapy for pros-
tate cancer had their toxicity assessed during treatment.
Of these, 26 patients were treated with non-IGRT before
implementation of the IGRT program and 265 were
treated with IGRT.
The 26 non-IGRT patients had pre-treatment ortho-
gonal verification imaging in the first week of radiother-
apy which was matched to bony anatomy on digitally
reconstructed radiographs (DRRs) from the planning CT
scan. The average bony anatomy displacement was cal-
culated and if more than 5 mm on average in the first
week then an isocentre move was made for the remain-
der of treatment. Pre-treatment orthogonal imaging was
conducted once a week after the first week to check for
setup accuracy during treatment.
The 265 IGRT patients had three cylindrical gold seed
fiducial markers measuring 1 mm diameter by 5 mm
length inserted into the base, apex and mid prostate one
week before the simulation CT scan. These three fidu-
cial markers were visible on the DRRs and also on daily
pretreatment orthogonal imaging. Image guided treat-
ment was conducted by image registration of the pre-
treatment orthogonal imaging with the corresponding
DRRs by three dimensional matching of fiducial marker
position and translation of the treatment couch to cor-
rect for displacement.
All patients followed a bowel emptying and bladder
filling protocol prior to simulation and each fraction of
treatment as reported previously [11]. Patients were
simulated supine with a bolster under knees and foot-
stocks fitted onto an immobilisation board (Combifix-
Sinmed, Civco, Kalona, IA). The simulation CT was
conducted at 3 mm spacing and 3 mm thickness. Pros-
tate, rectum and femoral heads delineation was per-
formed on the planning CT scan. The CTV was defined
as the prostate unless there were high risk features pre-
sent (T3, Gleason ≥8, PSA≥20), in which case the semi-
nal vesicles were included in the CTV. Intermediate risk
patients have the base of the seminal vesicles included.
Margins for CTV to PTV expansion were 10 mm cra-
nio-caudal, laterally and anterior, and 7 mm posteriorly.
Rectal volumes were contoured as a solid organ from
1.2 cm above the PTV to 1.2 cm below the PTV. Radio-
therapy was planned conformally, using 5 or 7 fields.
Rectal dose-volume histogram (DVH) constraints were
as follows: (i) 50% of rectal volume to receive less than
50 Gy; (ii) 30% of the volume to receive less than 60 Gy;
and (iii) 25% of the volume to receive less than 70 Gy.
No bladder dose-volume constraints were used in con-
formal radiotherapy planning. If the patient did not
meet rectal dose constraints on the conformal plan,
then the bladder was contoured and planning was per-
formed with intensity modulated radiotherapy (IMRT).
Hotspots were avoided on the bladder for IMRT. The
proportions treated with IMRT in both groups were
compared.
All patients were treated on Varian linear accelerators
(Varian Medical Systems, Palo Alto, USA). Non-IGRT
patients were prescribed 74 Gy in 2 Gy fractions five
days a week and IGRT patients were prescribed 78 Gy
in 2 Gy fractions five days a week. Although there was a
difference in total dose, toxicity was only assessed dur-
ing treatment and not after the completion of radiother-
apy. Therefore the two extra fractions in the IGRT arm
would not have impacted on the majority of assessments
which were conducted at approximately equal times in
both groups.
Toxicity Data Collection
Patient toxicity was recorded prospectively by nursing
staff, radiotherapy staff or medical staff at booked
weekly reviews or at additional reviews. Prior to the
introduction of toxicity data collection there was a train-
ing program conducted by our senior radiotherapy
n u r s e( M . L . ) .I nt h en o n - I G R Tg r o u p ,t o x i c i t yd a t aw a s
collected onto standardized paper assessment forms. In
the IGRT group, assessments were recorded electroni-
cally utilising the same assessment form on Impac
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Each assessment form had ten questions relating to
urinary frequency, cystitis, bladder spasm, urinary incon-
tinence, urinary retention, proctitis, anal skin discom-
fort, diarrhoea, haemorrhoid symptoms, and fatigue.
Patients were actively questioned for each of the ten
symptoms during each interview. To minimise observer
bias, the assessment forms themselves detailed the speci-
fics of each grade of toxicity, so that the assessor could
directly compare and choose the most appropriate grade
of toxicity for the patient in front of them.
All symptoms were scored according to the Common
Terminology Criteria for Adverse Events V3.0 [12].
Details of the data extraction process from Impac onto
a Microsoft Access database (Microsoft Corporation,
Redmond, WA) have been published by our group [13].
Statistical Methods
IGRT and non-IGRT patients’ T stage, Gleason score
and PSA were compared by Wilcoxon rank sum test.
History of transurethral resection of the prostate
(TURP), neoadjuvant luteinizing hormone releasing hor-
mone (LHRH) agonist, diabetes and hypertension were
compared by Fisher’s exact test. Frequency of IMRT use
between IGRT and non-IGRT groups was tested by
Fisher’s exact test. Patients with > G1 (greater than
grade 1) toxicity at baseline or those with only one day
of toxicity information were not included in the analysis
for that toxicity as the focus was on analysing change in
symptoms occurring during radiotherapy.
Severity of toxicity
Two methods were used to report toxicity severity.
Firstly we tabulated the frequencies of experiencing at
least one ≥G2 or ≥G3 toxicity event for each individual
toxicity. These frequencies were compared between
IGRT and non-IGRT groups using Fisher’s exact test.
Secondly, we grouped urinary frequency, cystitis, urin-
ary incontinence, urinary retention and bladder spasm
as GU, and proctitis and diarrhoea as GI toxicities, and
reported the overall maximum GU toxicity and maxi-
mum GI toxicity for all patients. This was to enable the
results of our study to be compared to results from
other studies, where acute toxicity had been reported in
this form.
Duration of toxicity
Duration of toxicity was measured as the number of
days from onset of a G2 or G3 toxicity until the grade
of toxicity returned to less than grade 2, or the end of
treatment if it did not improve. We assume that toxicity
onset is usually gradual therefore the first reported non-
zero toxicity is taken to have appeared midway between
the day that the toxicity was recorded and the Friday of
t h ep r e v i o u sw e e k .W h e r eac h a n g ei nt o x i c i t yg r a d e
occurred, the duration was calculated as the halfway
point between change from one grade of toxicity to
another.
For each toxicity and for each patient the number of
days a patient experienced a ≥G2 toxicity or ≥G3 toxi-
city was calculated. The Wilcoxon rank sum test was
used to test for a difference in the median number of
days of each toxicity between the IGRT and non-IGRT
groups.
If the toxicity lasted until the end of treatment, then
Day 53 is considered the end of the treatment period
f o rI G R Tp a t i e n t s .F o rn o n - I G R Tp a t i e n t s ,d a y5 1i s
considered the end of the treatment period because
IGRT patients receive 39 fractions of 2 Gy and non-
IGRT patients receive only 37 fractions of 2 Gy. There-
fore for patients who had a ≥G2 toxicity until the end of
treatment, the duration of toxicity would automatically
be 2 days longer in the IGRT group, because treatment
was 2 days longer.
Results
Of the 265 IGRT and 26 non-IGRT patients, 16 patients
were excluded from the IGRT group because they only
had one toxicity assessment during treatment. A further
15 toxicities were excluded from the IGRT group and 3
toxicities were excluded from the non-IGRT group
because these toxicities were > G1 at baseline. In total,
after exclusions, the IGRT group had 14228 toxicity
assessments analysed from 1432 assessment days from
249 patients and the non-IGRT group had 1893 toxicity
assessment analysed from 192 assessment days from 26
patients.
Patient baseline characteristics are tabulated in table 1.
The difference between T stage, Gleason score and PSA
were not statistically significant by Wilcoxon rank sum
test (p = 0.8987, p = 0.5782 and p = 0.661 respectively).
History of TURP, neoadjuvant LHRH agonist, diabetes
and hypertension were not significantly different
between IGRT and non-IGRT patients by Fisher’se x a c t
test (p = .0.8043, 0.5407, 0.4656, 0.6827 respectively).
There were 12% of patients who were treated with
IMRT in the non-IGRT arm and 4% in the IGRT arm.
This difference was not statistically significantly by Fish-
er’s exact test (p value of 0.191).
Table 2 shows the frequency ≥ G2 and ≥ G3 for all
ten toxicities. ≥ G3 urinary frequency, ≥ G2 diarrhoea
and ≥ G2 fatigue were significantly more common in
the non-IGRT group than the IGRT group. ≥ G3 urin-
ary frequency was three times more common in the
non-IGRT group compared to the IGRT group (23% vs.
7% p = 0.0188). Urinary frequency and cystitis were the
most common toxicities and ≥ G3 events only occurred
for urinary frequency and cystitis. There was no
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between the groups. Of the rectal symptoms, diarrhoea
(15% vs. 3% p = 0.0174) was more common in the non-
IGRT groups than the IGRT group. Fatigue ≥ G2 was
also three times more common in the non-IGRT group
compared to the IGRT group (23% vs. 8% p = 0.0271).
We grouped all urinary symptoms as GU toxicities, and
all rectal symptoms as GI toxicities. Table 3 shows the
grouped frequencies of GI and GU toxicities for IGRT and
non-IGRT. Overall, GU toxicities were more common
that GI toxicities, and also more severe. Most patients
experienced a GU toxicity during treatment, 93% for
IGRT and 96% for non-IGRT. Although IGRT patients
had a higher rate of G2 GU toxicities (54% vs. 38%), this
group had relatively less G3 GU toxicities (9% vs. 23%)
compared to the non-IGRT group. As more severe toxici-
ties were less common in the IGRT group, there were
more patients who experienced less severe toxicity.
There were no grade 3 or 4 GI toxicities. G2 GI toxicity
was half as common in the IGRT group compared to the
non-IGRT group (9% vs. 19%). Proportionally there were
more patients with G1 GI toxicities in the IGRT group,
compared to the non-IGRT group, because of less
patients in the IGRT group with more severe toxicity.
Table 4 shows the median number of days and inter-
quartile ranges for toxicities of ≥ G2; only considering
patients who had the toxicity. The duration of treatment
was longer for the IGRT group compared to the non-
IGRT group by 2 days. Despite this, patients in the IGRT
group had a shorter duration of toxicity overall compared
to patients in the non-IGRT group as shown in table 4.
The median number of days with a ≥ G2 toxicity was sig-
nificantly shorter by Wilcoxon rank sum test for ≥ G2 (p
= 0.0179) and ≥ G3 frequency (p = 0.0027), ≥ G2 diar-
rhoea (p = 0.0033) and ≥ G2 fatigue (p = 0.0088) in
favour of the IGRT group. This result means that these
symptoms occurred later in the treatment course for
IGRT patients compared to non-IGRT patients.
Discussion
In our study, urinary frequency, diarrhoea and fatigue
occurred less in patients treated with IGRT than in
Table 1 Comparison of patient baseline characteristics in
the IGRT and non-IGRT groups
T stage IGRT Non-IGRT P value
1 78(30%) 9(35%)
2 137(52%) 13(50%)
3a 40(15%) 3(12%)
3b 6(2%) 0(0%)
4 0(0%) 1(4%)
Not available 4(1%) 0
Total 265 26 0.8987
Gleason
≤ 6 61(23%) 9(35%)
7 147(55%) 11(42%)
8 31(12%) 2(8%)
9 21(8%) 3(12%)
10 1(0.4%) 1(4%)
Not available 4(1%) 0
Total 265 26 0.5782
PSA (ng/ml)
< 4 13(5%) 0(0%)
4-10 126(48%) 14(54%)
10.1-20 85(32%) 8(31%)
> 20 37(14%) 4(15%)
Not available 4(1%) 0
Total 265 26 0.661
Prior TURP 56 (21%) 6 (23%) 0.8043
Neoadjuvant LHRH agonist 131 (50%) 11 (42%) 0.5407
Diabetes 61 (23%) 4 (15%) 0.4656
Hypertension 145 (55%) 13 (50%) 0.6827
Table 2 Fisher’s exact test comparing the difference in
proportions of patients experiencing at least one toxicity
event in IGRT and non-IGRT groups
Toxicity % ≥ grade 2
IGRT non-IGRT p-
value
% ≥ grade 3
IGRT non-IGRT p-
value
Urinary frequency 35 52 0.1144 7 23 0.0188
Cystitis 47 42 0.6857 1 4 0.3243
Bladder spasm 1 0 1 0 0 NE*
Urinary incontinence 3 0 1 0 0 NE
Urinary retention 7 0 0.3825 0 0 NE
Proctitis 6 15 0.0862 0 0 NE
Anal skin 8 8 1 0 0 NE
Diarrhoea 3 15 0.0174 0 0 NE
Haemorrhoid symptoms 4 8 0.3097 0 0 NE
Fatigue 8 23 0.0271 0 0 NE
*NE = No grade 3 events.
Table 3 Overall maximum toxicity during treatment:
genitourinary (GU) and gastrointestinal (GI)
GU toxicity GI toxicity
Grade of toxicity Non-IGRT IGRT Non-IGRT IGRT
Grade 0 1(4%) 19(7%) 12(46%) 115(42%)
Grade 1 9(35%) 80(30%) 9(35%) 132(49%)
Grade 2 10(38%) 145(54%) 5(19%) 23(9%)
Grade 3 6(23%) 23(9%) 0 0
Grade 4 0 0 0 0
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efit appeared to be approximately 2/3 less for all three
toxicities. We would expect rectal and bladder side
effects to be less with IGRT compared to non-IGRT
because IGRT not only reduces the chance of geogra-
phical miss of the target but also reduces inadvertent
dose deposition in the adjacent normal tissues [14]. Fati-
gue is a systemic effect but it may be associated with
urinary frequency or diarrhoea because of loss of sleep
from nocturia or depletion of electrolytes caused by
severe diarrhoea. As patients with a baseline toxicity >
G1 were excluded from the analysis for that toxicity, it
is likely that the maximal toxicity experienced was
caused by radiotherapy treatment, as the symptom or
symptoms appeared during treatment. The time related
analysis and severity analysis were done separately and
both were independently significant in favour of IGRT
making it less likely that the benefit seen occurred by
chance. Organ toxicity is a function of the dose received
[ 1 5 ] ,a n dt h ev o l u m eo ft i s s u ei r r a d i a t e d[ 1 6 ] .
Considering that side effects are dose related, our data
suggests that organs at risk are getting less dose during
treatment with IGRT compared to non-IGRT in this
study.
Table 5 compares the results from our study with
acute toxicity results from other studies employing
IGRT for prostate cancer. As mentioned in the intro-
duction, it is not fully applicable to compare toxicity
results across studies, because of the differences in
methodology and protocols used in these studies. How-
ever as illustrated, the results in the present study are
not vastly dissimilar from results in other non-rando-
mized studies employing IGRT, whereby G3 and G4
toxicities are uncommon.
The largest limitation of our study is that it is not a
randomized study. We have tried to limit the confound-
ing factors by demonstrating that the patients were not
preselected, and that the T stage, Gleason score, PSA,
history of TURP, LHRH agonist, diabetes and hyperten-
sion were identical between groups. Although there was
Table 4 Medians number of days and interquartile ranges for toxicities of ≥ G2
Toxicity IGRT Non-IGRT P value
(Wilcoxon Rank Sum test)
Median Interquartile range Median Interquartile range
Urinary frequency 14.5 10 - 26.5 28 23.4 - 32.9 0.0179
Cystitis 15 8.5 - 27 24.5 19.3 - 31.3 0.7603
Bladder spasm 8.8 8.1 - 9.4 No events - 0.6566
Urinary incontinence 10.5 7.8 - 15.3 No events - 0.3919
Urinary retention 8.5 6 - 15.5 No events - 0.1746
Proctitis 10.5 7.8 - 18 20.8 11.5 - 28.4 0.0616
Anal skin 8.8 6.9 - 18.3 23.3 20.9 - 25.6 0.9308
Diarrhoea 10.3 4.8 - 10.6 9.3 7 - 12.9 0.0033
Haemorrhoid symptoms 15.5 8.6 - 25.6 26 17 - 35 0.3583
Fatigue 10.8 7.4 - 14 18.8 15.1 - 22 0.0088
Table 5 Comparison to results from other studies using IGRT for prostate cancer
Study Method Acute toxicity GU
by grade (%)
Acute toxicity GI
by grade (%)
2 3423 4
Present study (IGRT)
(n = 249)
96% conformal RT fiducials 78 Gy 54 9 0 9 0 0
Lips et al. (5)
(n = 331)
IMRT fiducials
76 Gy
47 3 0 30 0 0
Soete et al. (6)
(n = 238)
IG Arc therapy 37 16 0 19 6 0
Ghadjar et al. (7)
(n = 39)
IMRT fiducials 80 Gy 56 8 0 3 0 0
Cheng et al. (8)
(n = 76)
Tomotherapy
78.9 Gy
38 0 0 25 0 0
Martin et al. (9)
(n = 259)
87% conformal RT fiducials 79.8 Gy 33 0 0 10 0 0
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and non-IMRT, the difference was not statistically sig-
nificant. In addition, the use of IMRT did not change
the dose constraints for organs at risk, and therefore
similar doses were allowed to organs at risk with IMRT
and without IMRT in this study and no patient would
have received grossly outlying organ at risk doses. The
second limitation is that there was a substantially smal-
ler number of patients in the non-IGRT group (n = 26)
c o m p a r e dt ot h eI G R Tg r o u p( n=2 4 9 ) .T h ee f f e c to fa
small sample size is to reduce the power to detect a dif-
ference in toxicity between the two groups, especially
for toxicities that occurred less frequently. For example,
proctitis and flare of haemorrhoids were also more com-
m o ni nt h en o n - I G R Tg r o u pc o m p a r e dt ot h eI G R T
group, although the difference did not reach statistical
significance. If we had more patients in the non-IGRT
group, we may have had a greater ability to detect a dif-
ference in toxicity level for the less common acute toxi-
cities of radiotherapy.
Several randomised controlled trials and one meta-
analysis have demonstrated better biochemical control
for dose escalation in prostate cancer radiotherapy
[17-21]. However, toxicity is a serious concern in pros-
tate cancer patients receiving dose escalated radiother-
apy despite better biochemical control. The lower
toxicity for IGRT in our study was found despite the
higher total dose in the IGRT arm. The two extra frac-
tions at the end of treatment are more likely to have an
effect on late reactions. In dose escalation studies with
total dose of 74 Gy to 79.2 Gy, 17-33% of patients had a
≥ G2 late GI toxicity and 11-30% had a ≥ G2 late GU
toxicity [17-21]. Several studies have shown that acute
toxicity is predictive of late toxicity in prostate cancer
patients undergoing radiotherapy [22-25]. In a Trans-
Tasman Radiation Oncology Group (TROG) study, ≥
G2 acute toxicity was associated with a greater than
threefold risk of the subsequent development of late
toxicity [22]. Of patients developing late toxicity, 79%
had acute toxicity of ≥ G2. This is not surprising, as the
side effects experienced acutely are a function of dose
and inherent patient sensitivity and the side effects
experienced later on are also a function of dose and sen-
sitivity. In a Dutch study, 75% of men given a choice
between two doses of radiotherapy for prostate cancer
c h o s et oh a v et h el o w e rd o s ew i t ht h el o w e rc u r er a t e
over bladder and bowel treatment related side effects
[26]. IGRT is one method which may possibly reduce
toxicity whilst maintaining dose escalation.
Conclusion
In the context of a dose escalation in the IGRT group
from 74Gy to 78Gy, compared to non-IGRT, prostate
cancer patients treated radically with IGRT had lesser
diarrhoea, urinary frequency and lethargy during radio-
therapy despite the same CTV to PTV margin in both
groups. IGRT should be the standard of practice in
dose-escalated radiotherapy.
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